Ashwani Kumar Arora

771 total citations
39 papers, 553 citations indexed

About

Ashwani Kumar Arora is a scholar working on Epidemiology, Microbiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ashwani Kumar Arora has authored 39 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 11 papers in Microbiology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ashwani Kumar Arora's work include Influenza Virus Research Studies (20 papers), Respiratory viral infections research (15 papers) and Pneumonia and Respiratory Infections (13 papers). Ashwani Kumar Arora is often cited by papers focused on Influenza Virus Research Studies (20 papers), Respiratory viral infections research (15 papers) and Pneumonia and Respiratory Infections (13 papers). Ashwani Kumar Arora collaborates with scholars based in Italy, United States and Belgium. Ashwani Kumar Arora's co-authors include Eduardo Forleo‐Neto, Vas Narasimhan, Humberto Reynales, Nancy Bermal, Uwe Nicolay, Sharon E. Frey, Paola Pedotti, Maria Lattanzi, Geert Leroux‐Roels and Annaelisa Tasciotti and has published in prestigious journals such as Clinical Infectious Diseases, Water Resources Research and Frontiers in Microbiology.

In The Last Decade

Ashwani Kumar Arora

36 papers receiving 532 citations

Peers

Countries citing papers authored by Ashwani Kumar Arora

Since Specialization

Citations

This map shows the geographic impact of Ashwani Kumar Arora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashwani Kumar Arora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashwani Kumar Arora more than expected).

Fields of papers citing papers by Ashwani Kumar Arora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashwani Kumar Arora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashwani Kumar Arora. The network helps show where Ashwani Kumar Arora may publish in the future.

Co-authorship network of co-authors of Ashwani Kumar Arora

This figure shows the co-authorship network connecting the top 25 collaborators of Ashwani Kumar Arora. A scholar is included among the top collaborators of Ashwani Kumar Arora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashwani Kumar Arora. Ashwani Kumar Arora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lung mucosal immunity to NTHi vaccine antigens: Antibodies in sputum of chronic obstructive pulmonary disease patients 2024 ·Human Vaccines & Immunotherapeutics ·(unknown), Cecilia Buonsanti, (unknown), Susanna Aprea, (unknown), (unknown), Mario Contorni, Simona Rondini, Ashwani Kumar Arora, Monia Bardelli, Oretta Finco, Davide Serruto, Silvia Rossi Paccani	2
2	Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes 2024 ·Drugs in R&D ·(unknown), Alimamy Serry-Bangura, Bassey Edem, (unknown), (unknown), Danilo Gomes Moriel, Audino Podda, Iris De Ryck, Ashwani Kumar Arora	1
3	A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial 2022 ·Vaccine ·Ashwani Kumar Arora, Kenneth Chinsky, Claus Keller, Irvin Mayers, Sergi Pascual-Guàrdia, (unknown), Christophe Lambert, (unknown), Simona Rondini, (unknown), Fernando Ulloa‐Montoya, (unknown), Daniela Casula	4
4	Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study 2022 ·Respiratory Research ·(unknown), (unknown), Daniela Casula, (unknown), Michel Janssens, Annaelisa Tasciotti, Tino F. Schwarz, Murdo Ferguson, Ashwani Kumar Arora	4
5	Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints 2021 ·Respiratory Research ·(unknown), (unknown), (unknown), Tom Wilkinson, Ashwani Kumar Arora, (unknown)	7
6	Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial 2021 ·Vaccine X ·Philippe De Smedt, Geert Leroux‐Roels, Corinne Vandermeulen, Annaelisa Tasciotti, (unknown), Marie Dozot, Daniela Casula, (unknown), (unknown), Ashwani Kumar Arora	6
7	Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial 2019 ·Vaccine ·Tom Wilkinson, Stuart Schembri, Christopher E. Brightling, Nawar Diar Bakerly, Keir Lewis, William MacNee, Lars Rombo, Jan Hedner, Martin Allen, Paul Walker, Iris De Ryck, Annaelisa Tasciotti, Daniela Casula, Philippe Moris, Marco Testa, Ashwani Kumar Arora	41
8	Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine 2019 ·Vaccine ·Pierre Van Damme, Geert Leroux‐Roels, Corinne Vandermeulen, Iris De Ryck, Annaelisa Tasciotti, Marie Dozot, (unknown), Marco Testa, Ashwani Kumar Arora	30
9	Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults 2018 ·PLoS neglected tropical diseases ·(unknown), Pornthep Chanthavanich, (unknown), (unknown), Delia Yu, (unknown), (unknown), Daniela Casula, Ashwani Kumar Arora, Michele Pellegrini	9
10	Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea—A randomised trial 2016 ·Vaccine ·Hoan Jong Lee, Young June Choe, (unknown), Kyung‐Hyo Kim, Su Eun Park, Yun Kyung Kim, Chi Eun Oh, Hyunju Lee, (unknown), Hans L. Bock, Daniela Casula, (unknown), Ashwani Kumar Arora	13
11	Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children 2015 ·Human Vaccines & Immunotherapeutics ·Markus Knuf, Geert Leroux‐Roels, H. C. Rümke, Luis Rivera, Paola Pedotti, Ashwani Kumar Arora, Maria Lattanzi, Dorothee Kieninger, Giovanni Della Cioppa	11
12	Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years 2015 ·International Journal of Infectious Diseases ·Sanjay Lalwani, Sharad Agarkhedkar, Nithya Gogtay, Sonali Palkar, (unknown), Urmila Thatte, (unknown), (unknown), Paola Pedotti, Margaret Hoyle, (unknown), Ashwani Kumar Arora	14
13	Influenza vaccination in children primed with MF59^®-adjuvanted or non-adjuvanted seasonal influenza vaccine 2015 ·Human Vaccines & Immunotherapeutics ·Timo Vesikari, Aino Forstén, Ashwani Kumar Arora, Theodore F. Tsai, Ralf Clemens	21
14	Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age 2014 ·The Pediatric Infectious Disease Journal ·Markus Knuf, Geert Leroux‐Roels, H. C. Rümke, Katia Abarca, Luis Rivera, Maria Lattanzi, Paola Pedotti, Ashwani Kumar Arora, Dorothee Kieninger‐Baum, Giovanni Della Cioppa	10
15	Safety and immunogenicity of meningococcal ACWY CRM₁₉₇-conjugate vaccine in children, adolescents and adults in Russia 2014 ·Human Vaccines & Immunotherapeutics ·(unknown), С. М. Харит, Leyla S. Namazova-Baranova, (unknown), (unknown), (unknown), (unknown), Ashwani Kumar Arora	11
16	Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects 2014 ·Vaccine ·Sharon E. Frey, (unknown), Humberto Reynales, Nancy Bermal, Uwe Nicolay, Vas Narasimhan, Eduardo Forleo‐Neto, Ashwani Kumar Arora	110
17	Safety and Immunogenicity of Typhoid Fever and Yellow Fever Vaccines When Administered Concomitantly With Quadrivalent Meningococcal ACWY Glycoconjugate Vaccine in Healthy Adults 2014 ·Journal of Travel Medicine ·Martin Alberer, Gerd Burchard, Tomáš Jelı́nek, Emil C. Reisinger, Jiřı́ Beran, (unknown), Eduardo Forleo‐Neto, Alemnew F. Dagnew, Ashwani Kumar Arora	11
18	Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: A randomized, open-label, multi-center study 2014 ·Travel Medicine and Infectious Disease ·Martin Alberer, Gerd Burchard, Tomáš Jelı́nek, Emil C. Reisinger, Jiřı́ Beran, Seetha Meyer, Eduardo Forleo‐Neto, Dieter Gniel, Alemnew F. Dagnew, Ashwani Kumar Arora	15
19	Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age 2014 ·Vaccine ·Markus Knuf, Geert Leroux‐Roels, H. C. Rümke, Katia Abarca, Luis Rivera, Maria Lattanzi, Paola Pedotti, Ashwani Kumar Arora, Dorothee Kieninger‐Baum, Giovanni Della Cioppa	17
20	The ‘gap’ in plasma osmolar gap! 2013 ·European Journal of Internal Medicine ·Ashwani Kumar Arora	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact